Perspective Therapeutics Inc. (CATX)
NYSE: CATXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CATX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $91.03M
- EPS (TTM)
- -$1.25
- Dividend yield
- None
- 52-week range
- 0.73 – 6.16
- Day range
- 0.7407 – 0.79
- Volume / Avg
- 1.39M / 2.70M
- Beta
- —
- Shares outstanding
- 120.76M
52-week range
CATX stock today
On Nov 20, CATX ended the session at $0.7538, shedding $0.0302 (3.85%), versus the S&P 500's 3.70% decline. At this level, CATX sits near the bottom of its 52-week range of $0.73 to $6.16: 87.8% below the high, set on Jan 29, 2026 and 3.3% above the low. CATX is down 72.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.9%.
Perspective Therapeutics has posted a net loss over the last twelve months (EPS of -$1.25), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Perspective Therapeutics
Company profilePerspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Johan M. Spoor
- Headquarters
- Seattle, WA
- Employees
- 163
- Website
- perspectivetherapeutics.com
Financial highlights
Full financialsPerspective Therapeutics reported a net loss of $103.1 million, compared with a loss of $79.3 million a year earlier. Diluted earnings per share came in at -$1.40.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | $1.43M | $0 | $10.79M |
| Growth | — | — | — | -100.00% | +7.38% |
| Net income | $-103.12M | $-79.28M | $-46.51M | $-10.76M | $-7.27M |
| EPS (diluted) | $-1.40 | $-1.23 | $-1.74 | — | — |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$9.71+1188.14%
- Strong buy 1
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.27 vs $-0.24
- Surprise
- -12.50%
CATX news
All CATX news- Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 ResultsNasdaqCATX, MKC.V
- Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 ResultsGlobeNewswire
- Perspective Therapeutics, Inc. Announces Updated Interim Phase 1/2a Data for [212Pb]Lapemelanotide Zapixetar (VMT01) in Advanced MelanomaNasdaq
- Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026GlobeNewswire
- Perspective Therapeutics, Inc. Presents Incremental Phase 1/2a Data for [212Pb]Bamzireotide NavoxetanNasdaq
- Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETsGlobeNewswire
- Perspective Therapeutics Consensus Price Target Decreased by 13.02% to $10.78Nasdaq
- Perspective Therapeutics, Inc. Announces Interim Phase 1/2a Results for [212Pb]VMT-α-NETNasdaq
Perspective Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NTHINeOnc Technologies Holdings Inc. | 3.15 | -9.48% | $90.88M | vs CATX |
| CLLSCellectis S.A. ADR | 0.9209 | -7.89% | $92.76M | vs CATX |
| DERMJourney Medical Corporation | 3.30 | -7.04% | $93.16M | vs CATX |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs CATX |
| RTSNRetension Pharmaceuticals Inc. | 10.51 | -19.22% | $87.57M | vs CATX |
| EQEquillium Inc. | 1.06 | -5.36% | $87.26M | vs CATX |
| UPBUpstream Bio Inc. | 1.59 | -20.50% | $87.15M | vs CATX |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs CATX |
Indexes, lists and sector
Perspective Therapeutics stock FAQ
What is Perspective Therapeutics's stock price today?
CATX last traded at $0.7538 as of Nov 20, 4:00 PM EST, down 3.85% on the day. Prices are delayed at least 15 minutes.
Does Perspective Therapeutics pay a dividend?
No. Perspective Therapeutics does not currently pay a regular cash dividend.
Who is Perspective Therapeutics's CEO?
Mr. Johan M. Spoor is the chief executive officer of Perspective Therapeutics Inc., which has about 163 employees.
Has CATX ever split its stock?
Yes. The most recent CATX stock split was a 1-for-10 split on Jun 17, 2024.
What is the CATX 52-week high?
The 52-week high for CATX is $6.16 and the 52-week low is $0.73. The stock is currently 87.8% below its high.